These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 12170431)

  • 1. Hematologic malignancies: new developments and future treatments.
    Cheson BD
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):33-45. PubMed ID: 12170431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
    Aivado M; Schulte K; Henze L; Burger J; Finke J; Haas R
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):19-22. PubMed ID: 12170428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibitors in the treatment of B-cell malignancies.
    Schenkein D
    Clin Lymphoma; 2002 Jun; 3(1):49-55. PubMed ID: 12141956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy.
    Kahl BS; Cheson BD; Friedberg JW
    Clin Adv Hematol Oncol; 2010 May; 8(5):1-16. PubMed ID: 20712081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovative strategies in lymphoma therapy.
    J├Ąger U
    Wien Klin Wochenschr; 2003 Aug; 115(13-14):462-70. PubMed ID: 13677264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the proteasome inhibitor bortezomib in hematologic malignancies.
    Goy A; Gilles F
    Clin Lymphoma; 2004 Mar; 4(4):230-7. PubMed ID: 15072615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New drugs in acute myeloid leukemia.
    Giles FJ
    Curr Oncol Rep; 2002 Sep; 4(5):369-74. PubMed ID: 12162909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Coleman M
    Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
    Fanale MA; Younes A
    Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibody therapy in lymphoid malignancies.
    Hainsworth JD
    Oncologist; 2000; 5(5):376-84. PubMed ID: 11040273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.
    Rummel MJ; Mitrou PS; Hoelzer D
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):27-32. PubMed ID: 12170430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bendamustine in the treatment of hematologic malignancies. Introduction.
    Diehl V; Cheson BD
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):1-3. PubMed ID: 12170424
    [No Abstract]   [Full Text] [Related]  

  • 14. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Elefante A; Czuczman MS
    Am J Health Syst Pharm; 2010 May; 67(9):713-23. PubMed ID: 20410545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-based therapy of non-Hodgkin's lymphoma.
    Foran JM
    Best Pract Res Clin Haematol; 2002 Sep; 15(3):449-65. PubMed ID: 12468399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.
    Hoy SM
    Drugs; 2012 Oct; 72(14):1929-50. PubMed ID: 22950536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current development of new drugs in malignant lymphoma].
    Ogura M
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():715-30. PubMed ID: 23134034
    [No Abstract]   [Full Text] [Related]  

  • 18. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Bremer K
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib for the treatment of non-Hodgkin's lymphoma.
    Bose P; Batalo MS; Holkova B; Grant S
    Expert Opin Pharmacother; 2014 Nov; 15(16):2443-59. PubMed ID: 25263936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
    Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
    MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.